Based on moderate-quality evidence, direct association seen for greater intensity of behavioral therapy with efficacy findings
Dulaglutide effective in preventing substantial weight gain, which was more common in women
Combination of a patch and fast-acting nicotine replacement therapy also effective
Cytisinicline well tolerated with only 2.9 percent of participants discontinuing due to an adverse event
Reduced risk seen for all CVD events, respiratory system disease events, hospitalization due to CVD or RSD, adverse birth outcomes
Adjusted prevalence of nicotine dependence was lower for those aged 18 to 25, 26 to 34, 35 to 49 versus those aged 50 and older
No significant difference in verified seven-day abstinence seen by treatment group among Black adults who smoke daily
Decreases in depression, anxiety seen, particularly in people with history of mental illness
App use tied to higher six-month biochemically verified sustained abstinence rate
However, early electronic cigarette quitters plus stable cigarette use was the most common trajectory in 41.6 percent of participants